X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2538) 2538
Book Review (515) 515
Publication (218) 218
Conference Proceeding (13) 13
Book Chapter (3) 3
Data Set (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (2202) 2202
index medicus (2191) 2191
humans (2025) 2025
oncology (1079) 1079
female (1036) 1036
male (886) 886
cancer (853) 853
vascular endothelial growth factor (722) 722
angiogenesis (669) 669
middle aged (669) 669
chemotherapy (638) 638
animals (599) 599
endothelial growth-factor (567) 567
aged (566) 566
antibodies, monoclonal, humanized (522) 522
ophthalmology (521) 521
angiogenesis inhibitors - therapeutic use (503) 503
care and treatment (481) 481
adult (473) 473
antibodies, monoclonal - therapeutic use (440) 440
vascular endothelial growth factor a - antagonists & inhibitors (412) 412
treatment outcome (407) 407
metastasis (405) 405
tumors (395) 395
research (385) 385
patients (361) 361
therapy (339) 339
mice (334) 334
vascular endothelial growth factor a - immunology (333) 333
antineoplastic combined chemotherapy protocols - therapeutic use (326) 326
colorectal cancer (324) 324
multidisciplinary sciences (320) 320
medicine (307) 307
survival (297) 297
analysis (295) 295
eye diseases (295) 295
research article (291) 291
vegf (282) 282
health aspects (269) 269
drug therapy (268) 268
science (267) 267
cancer therapies (264) 264
clinical trials (247) 247
surgery (247) 247
antineoplastic agents - therapeutic use (244) 244
expression (238) 238
angiogenesis inhibitors - administration & dosage (237) 237
genetic structures (237) 237
colorectal neoplasms - drug therapy (233) 233
vascular endothelial growth factor a - metabolism (232) 232
studies (225) 225
immunology (223) 223
antibodies, monoclonal - administration & dosage (217) 217
aged, 80 and over (216) 216
macular degeneration (214) 214
immunotherapy (213) 213
metastases (209) 209
cell line, tumor (208) 208
angiogenesis inhibitors (207) 207
antibodies, monoclonal, humanized - therapeutic use (206) 206
prognosis (200) 200
sense organs (196) 196
retrospective studies (191) 191
monoclonal antibodies (184) 184
colorectal neoplasms - pathology (182) 182
diagnosis (181) 181
ranibizumab (181) 181
disease-free survival (174) 174
pharmacology & pharmacy (173) 173
diabetic retinopathy (168) 168
trial (167) 167
angiogenesis inhibitors - pharmacology (166) 166
medical research (165) 165
antibodies, monoclonal, humanized - administration & dosage (164) 164
risk factors (164) 164
medicine & public health (162) 162
retina (159) 159
neovascularization, pathologic - drug therapy (158) 158
visual acuity (157) 157
neovascularization (156) 156
physiological aspects (156) 156
neoplasms - drug therapy (153) 153
cell biology (152) 152
neoplasm metastasis (152) 152
medicine, research & experimental (151) 151
usage (149) 149
development and progression (147) 147
intravitreal injections (147) 147
phase-ii (145) 145
biomarkers (144) 144
medicine and health sciences (144) 144
cetuximab (142) 142
follow-up studies (142) 142
breast cancer (141) 141
combination (139) 139
medical prognosis (139) 139
phase-ii trial (138) 138
angiogenesis inhibitors - adverse effects (137) 137
bevacizumab - administration & dosage (137) 137
metastatic colorectal-cancer (137) 137
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2463) 2463
Japanese (35) 35
French (18) 18
German (8) 8
Chinese (5) 5
Russian (2) 2
Slovak (2) 2
Spanish (2) 2
Czech (1) 1
Hungarian (1) 1
Icelandic (1) 1
Polish (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 10/2017, Volume 12, Issue 10, pp. e0186046 - e0186046
Administration of high dose intravenous immunoglobulin (IVIg) is widely used in the clinic to treat autoimmune and severe inflammatory diseases. However, its... 
B-CELLS | ANTIINFLAMMATORY ACTIVITY | ANTIIDIOTYPIC ANTIBODIES | MULTIDISCIPLINARY SCIENCES | T-CELL-ACTIVATION | IN-VIVO | MEDIATED AMELIORATION | THROMBOCYTOPENIC PURPURA | IGG-FC | INTRAVENOUS IMMUNOGLOBULIN IVIG | FC-GAMMA RECEPTOR | Bevacizumab - pharmacology | Adjuvants, Immunologic - pharmacology | Dose-Response Relationship, Immunologic | Spleen - immunology | Ovalbumin - immunology | Humans | Immunoglobulins, Intravenous - administration & dosage | Spleen - drug effects | CD4-Positive T-Lymphocytes - immunology | Epitopes - immunology | Female | Lymph Nodes - drug effects | Antibodies, Monoclonal - immunology | Antibody Formation - immunology | Antibodies, Monoclonal - pharmacology | Mice, Inbred C57BL | Lymph Nodes - immunology | Thymus Gland - drug effects | Animals | B-Lymphocytes - immunology | Antibody Formation - drug effects | Antigens - immunology | Thymus Gland - immunology | Immunoglobulins, Intravenous - immunology | Bevacizumab - immunology | Antigens | Immune response | Research | B cells | T cells | Analysis | Competition | Intravenous administration | Lymphocytes T | Arthritis | Vaccines | Lymph nodes | Inflammatory diseases | Antibody response | Cell activation | Immunology | Lymphocytes | Risk assessment | Drug dosages | Spleen | Antigen presentation | Ovalbumin | Immunization | Immunoglobulins | Dendritic cells | Immunomodulation | CD4 antigen | Mode of action | Immune systems | Drainage | Studies | Lymphocytes B | Monoclonal antibodies | Autoimmune diseases | Human behavior | Index Medicus
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 8/2008, Volume 57, Issue 8, pp. 1115 - 1124
Impairment of dendritic cells (DC), the most effective activators of anticancer immune responses, is one mechanism for defective antitumor immunity, but the... 
Dendritic cell | Immature myeloid cell | Biomedicine | Immunology | VEGF | Oncology | Cancer Research | Immunity | Cancer | PROGENITOR CELLS | immunity | COLORECTAL-CARCINOMA | IMMUNOLOGY | MATURATION | D-DIMER LEVELS | BREAST-CANCER | immature myeloid cell | PLASMINOGEN-ACTIVATOR | ONCOLOGY | IMMUNE SUPPRESSION | IN-VIVO | cancer | DIFFERENTIATION | dendritic cell | ENDOTHELIAL GROWTH-FACTOR | Breast Neoplasms - immunology | Dendritic Cells - immunology | Humans | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Angiogenesis Inhibitors - administration & dosage | Colorectal Neoplasms - therapy | T-Lymphocytes - drug effects | Immunotherapy | Myeloid Progenitor Cells - immunology | Dendritic Cells - drug effects | Urokinase-Type Plasminogen Activator - immunology | Neovascularization, Pathologic - immunology | Urokinase-Type Plasminogen Activator - blood | Colorectal Neoplasms - blood | Antibodies, Monoclonal - pharmacology | Fibrin Fibrinogen Degradation Products - analysis | Cells, Cultured | Vascular Endothelial Growth Factor A - blood | Angiogenesis Inhibitors - pharmacology | Vascular Endothelial Growth Factor A - immunology | Lung Neoplasms - therapy | Plasminogen Activator Inhibitor 1 - blood | Lung Neoplasms - immunology | Pilot Projects | Colorectal Neoplasms - immunology | Myeloid Progenitor Cells - drug effects | Antibodies, Monoclonal - administration & dosage | Cell Differentiation - drug effects | Breast Neoplasms - blood | T-Lymphocytes - immunology | Cell Proliferation - drug effects | Lung Neoplasms - blood | Plasminogen Activator Inhibitor 1 - immunology | Care and treatment | Dendritic cells | Vascular endothelial growth factor | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 08/2010, Volume 70, Issue 15, pp. 6171 - 6180
Journal Article
Angiogenesis, ISSN 0969-6970, 6/2012, Volume 15, Issue 2, pp. 171 - 185
Pharmacological inhibition of VEGF-A has proven to be effective in inhibiting angiogenesis and vascular leak associated with cancers and various eye diseases.... 
Biomedicine | Age-related macular degeneration | Cancer Research | Oncology | Affinity | Ophthalmology | VEGF receptor | Cardiology | Aflibercept | Placental growth factor | Biomedicine general | Cell Biology | ANGIOGENESIS | EFFICACY | MACULAR DEGENERATION | PHASE-II | ANTIBODY | FACTOR THERAPY | EYE | IN-VITRO | PEGAPTANIB | RETINAL DISEASES | PERIPHERAL VASCULAR DISEASE | Angiogenesis Inhibitors - immunology | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor B - antagonists & inhibitors | Recombinant Fusion Proteins - pharmacology | Endothelial Cells - metabolism | Humans | Angiogenesis Inhibitors - pharmacology | Vascular Endothelial Growth Factor B - immunology | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Vascular Endothelial Growth Factor A - immunology | Vascular Endothelial Growth Factor Receptor-1 - metabolism | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Vascular Endothelial Growth Factor Receptor-2 - immunology | Enzyme Activation - drug effects | Bevacizumab | Endothelial Cells - immunology | Vascular Endothelial Growth Factor B - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | HEK293 Cells | Ranibizumab | Vascular Endothelial Growth Factor Receptor-1 - immunology | Antibodies, Monoclonal, Humanized - immunology | Index Medicus | Original Paper
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2012, Volume 109, Issue 41, pp. 16642 - 16647
The deregulation of the epidermal growth factor receptor (EGFR) has a significant role in the progression of tumors. Despite the development of a number of... 
Tumor burden | Bioluminescence | Cell growth | NIH 3T3 cells | Imaging | Medical treatment | Cell lines | Stem cells | Tumors | Cancer | LUNG-CANCER | CETUXIMAB | GROWTH-FACTOR-RECEPTOR | GLIOBLASTOMA-MULTIFORME | BEVACIZUMAB | MULTIDISCIPLINARY SCIENCES | IN-VIVO | RESISTANCE | ANTIBODY | BLOOD-BRAIN-BARRIER | PROGRESSION | NIH 3T3 Cells | Single-Domain Antibodies - metabolism | Humans | Brain Neoplasms - pathology | Green Fluorescent Proteins - genetics | Single-Domain Antibodies - immunology | Immunoconjugates - immunology | Signal Transduction - immunology | Neural Stem Cells - immunology | Brain Neoplasms - immunology | HEK293 Cells | Neural Stem Cells - transplantation | Tumor Cells, Cultured | Green Fluorescent Proteins - metabolism | Receptor, Epidermal Growth Factor - immunology | Immunoconjugates - metabolism | Treatment Outcome | TNF-Related Apoptosis-Inducing Ligand - immunology | TNF-Related Apoptosis-Inducing Ligand - metabolism | Blotting, Western | Glioblastoma - therapy | Xenograft Model Antitumor Assays | Animals | Apoptosis - immunology | Glioblastoma - immunology | Mice, Nude | Glioblastoma - pathology | Immunoconjugates - genetics | Brain Neoplasms - therapy | Mice | Single-Domain Antibodies - genetics | Neural Stem Cells - metabolism | TNF-Related Apoptosis-Inducing Ligand - genetics | Microscopy, Fluorescence | Tumor Burden - immunology | Physiological aspects | Cytogenetics | Genetic aspects | Research | Gene expression | Health aspects | Rodents | Apoptosis | Index Medicus | Biological Sciences
Journal Article
Cancer Research, ISSN 0008-5472, 01/2015, Volume 75, Issue 1, pp. 159 - 170
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 11/2013, Volume 3, Issue 1, pp. 3380 - 3380
We developed DNA vaccine for vascular endothelial growth factor (VEGF), which may provide the therapeutic option instead of anti-VEGF antibody, bevacizumab.... 
RETINAL NEOVASCULARIZATION | THERAPY | OXYGEN-INDUCED RETINOPATHY | BEVACIZUMAB | MULTIDISCIPLINARY SCIENCES | TRAP | TUMOR VASCULATURE | COMBINATION | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Angiogenesis Inhibitors - immunology | Vaccines, DNA - immunology | Cercopithecus aethiops | Epitopes, B-Lymphocyte - immunology | Bevacizumab | Immunoglobulin G - immunology | Antibodies, Monoclonal, Humanized - pharmacology | Female | Neovascularization, Pathologic - immunology | Disease Models, Animal | Plasmids - immunology | Angiogenesis Inhibitors - pharmacology | Vascular Endothelial Growth Factor A - immunology | Hepatitis B Core Antigens - immunology | Neoplasms - drug therapy | Endothelial Cells - immunology | Animals | Neoplasms - immunology | Neovascularization, Pathologic - drug therapy | Mice | Mice, Inbred BALB C | Antibodies, Monoclonal, Humanized - immunology | COS Cells | Vaccines, DNA - pharmacology | Endothelial Cells - drug effects | Phosphorylation | Animal models | Retinopathy | Immunoglobulin G | Extracellular signal-regulated kinase | DNA vaccines | Vaccines | Survival | Endothelial cells | Vascularization | Angiogenesis | Lymphocytes B | Core protein | Colon | Vascular endothelial growth factor | Deoxyribonucleic acid--DNA | Hepatitis B | Cancer | Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 08/2016, Volume 7, Issue 1, pp. 12624 - 12624
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2012, Volume 7, Issue 12, pp. e51964 - e51964
Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the epidermal growth factor family and has a variety of physiological and... 
SMOOTH-MUSCLE | ATHEROSCLEROTIC PLAQUES | MULTIDISCIPLINARY SCIENCES | EPIDERMAL-GROWTH-FACTOR | ENDOTHELIAL-CELLS | TGF-ALPHA | TERMINAL FRAGMENT | OVARIAN-CANCER | DIPHTHERIA-TOXIN-RECEPTOR | BINDING | EXPRESSION | Human Umbilical Vein Endothelial Cells - metabolism | Humans | Human Umbilical Vein Endothelial Cells - immunology | Substrate Specificity | Neovascularization, Pathologic - pathology | Epitopes - immunology | Intercellular Signaling Peptides and Proteins - metabolism | Antibodies, Neutralizing - immunology | Receptor, Epidermal Growth Factor - metabolism | Neovascularization, Pathologic - immunology | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Antibodies, Monoclonal - immunology | Fibroblasts - metabolism | Protein Structure, Tertiary | Cell Line | Receptor, Epidermal Growth Factor - immunology | Human Umbilical Vein Endothelial Cells - drug effects | Antibodies, Monoclonal - pharmacology | Rats | Antibodies, Neutralizing - pharmacology | Neoplasms - blood supply | Neoplasms - drug therapy | Cross Reactions | Heparin-binding EGF-like Growth Factor | Animals | MAP Kinase Signaling System - drug effects | Proto-Oncogene Proteins c-akt - immunology | Neoplasms - immunology | Neovascularization, Pathologic - drug therapy | Fibroblasts - drug effects | Cell Line, Tumor | Fibroblasts - immunology | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Neovascularization, Pathologic - metabolism | Receptor, ErbB-4 | Intercellular Signaling Peptides and Proteins - immunology | Epidermal growth factor | Monoclonal antibodies | Anticoagulants (Medicine) | Comparative analysis | Health aspects | Vascular endothelial growth factor | Cancer | Antigenic determinants | Cell proliferation | Phosphorylation | Physiological effects | Amino acids | AKT protein | Selectivity | Amphiregulin | Bevacizumab | Ovarian cancer | Angiogenesis | Inhibition | Pharmaceutical industry | Binding | Alanine | Immunoglobulins | Epidermal growth factor receptors | Cross-reactivity | Extracellular signal-regulated kinase | Pharmacology | Breast cancer | Gene expression | Chemical compounds | ErbB-2 protein | Biological activity | Endothelial cells | Signaling | Mutagenesis | Heparin-binding epidermal growth factor-like growth factor | Neutralizing | Ligands | Heparin | Laboratory animals | Index Medicus
Journal Article
Journal Article